Brean Murray Initiates Idenix At Sell, $3 PT

June 17, 2011 7:38 AM | 8 seconds read |
Brean Murray Carret & Company has initiated coverage on Idenix Pharmaceuticals IDIX with a Sell rating and $3 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetInitiationAnalyst RatingsBiotechnologyBrean Murray Carret & CompanyHealth CareIdenix Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!